Diana Ernst

Mepolizumab was found to significantly reduce exacerbations in adults with chronic obstructive pulmonary disease (COPD), according to results from the MATINEE trial.

Tremfya ® (guselkumab) receives US FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease.

The FDA authorization was based on a clinical study that included 118 participants with perceived mild to moderate hearing loss. Results showed comparable perceived benefit between individuals who used the HAF self-fitting strategy and those who received professional fitting of the same device. Moreover, similar results were observed in both groups when testing the levels of amplification in the ear canal and an individual's ability to understand speech in a noisy environment.

(furosemide injection) to include treatment of congestion due to fluid overload in adult patients with chronic heart failure (CHF), regardless of New York Heart Association (NYHA) functional class. Previously, the novel furosemide delivery system was only indicated for patients with NYHA class II and class III CHF.

The approval in adolescent patients was based on evidence from the phase 3 SINUS-24 and SINUS-52 trials.

FDA approves Ocrevus Zunovo™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis.

Results from a confirmatory study show that dupilumab significantly reduces itch in patients with uncontrolled chronic spontaneous urticaria (CSU).

A study investigating GSK's investigational herpes simplex virus (HSV) vaccine candidate failed to meet its primary efficacy endpoint.

Treatment with dupilumab led to significant improvements in disease remission in patients with bullous pemphigoid, an autoimmune blistering skin disease.

Tecentriq Hybreza is supplied in a single-dose vial containing 1875 mg of atezolizumab and 30,000 units of hyaluronidase per 15 mL.